February 12, 2018 / 1:15 PM / 2 months ago

BRIEF-Avid Bioservices, Oncologie Enter Into Asset Assignment, Purchase Agreement For Avid's PS-Targeting Program Including Bavituximab

Feb 12 (Reuters) - Avid Bioservices Inc:

* AVID BIOSERVICES AND ONCOLOGIE ENTER INTO ASSET ASSIGNMENT AND PURCHASE AGREEMENT FOR AVID’S PS-TARGETING PROGRAM INCLUDING BAVITUXIMAB

* AVID BIOSERVICES INC - ‍AVID WILL RECEIVE $8 MILLION IN UPFRONT PAYMENTS FROM ONCOLOGIE PAID OVER A PERIOD OF SIX MONTHS FROM EXECUTION DATE OF AGREEMENT​

* AVID BIOSERVICES INC - ‍AVID WILL BE ELIGIBLE TO RECEIVE UP TO $95 MILLION IN DEVELOPMENT, REGULATORY AND COMMERCIALIZATION MILESTONES​

* AVID BIOSERVICES - ‍ONCOLOGIE TO BE RESPONSIBLE FOR FUTURE RESEARCH, DEVELOPMENT & COMMERCIALIZATION OF BAVITUXIMAB, RELATED INTELLECTUAL PROPERTY COSTS​

* AVID BIOSERVICES INC - ‍ONCOLOGIE WILL ENTER INTO DEAL WITH AVID FOR FUTURE CONTRACT DEVELOPMENT AND MANUFACTURING ACTIVITIES IN SUPPORT OF BAVITUXIMAB​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below